Department of Dermatology, King's College Hospital, London, UK.
Clin Exp Dermatol. 2023 Feb 2;48(2):96-99. doi: 10.1093/ced/llac046.
Palmoplantar viral warts are common, often affecting the quality of life of patients and present a major therapeutic challenge. Immunotherapy using diphencyprone (DCP) can be beneficial especially if first-line treatments fail.
To determine the effectiveness of DCP in clearing viral warts, and to provide detail on the number of treatments required and any adverse effects (AEs).
This was a retrospective case series of 124 patients who had received DCP treatment in a UK private practice setting from 1991 to 2008, carried out by a dermatologist experienced in the procedure. All patients had been referred by other clinicians after failure of standard treatments. The study data were extracted from clinical records, with follow-up until wart clearance or treatment discontinuation.
There was an equal distribution in sexes (63 females, 61 males), with 37% of patients having warts present for greater than 5 years. The majority (93%) of patients had already tried cryotherapy, which was unsuccessful in clearing warts completely in all cases. Following DCP treatment, 77% of patients achieved full eradication of their warts, including three patients who were immunosuppressed. The mean number of DCP treatments required to achieve full clearance was 4·7, and the mean concentration of DCP required was 4%. Only 12% of patients experienced AEs, which were mild, and included urticaria and blistering.
We suggest that DCP immunotherapy is a safe and effective treatment for eradicating viral warts, especially in recalcitrant cases.
掌跖部病毒性疣很常见，常影响患者的生活质量，是一种主要的治疗挑战。使用二苯环丙烯酮（DCP）的免疫疗法可能是有益的，特别是如果一线治疗失败。
确定 DCP 清除病毒性疣的有效性，并详细说明所需的治疗次数和任何不良反应（AE）。
这是一项回顾性病例系列研究，纳入了 1991 年至 2008 年在英国私人诊所接受 DCP 治疗的 124 例患者，由一位经验丰富的皮肤科医生进行。所有患者均在标准治疗失败后由其他临床医生转诊。研究数据从临床记录中提取，随访至疣清除或治疗停止。
男女比例相等（63 名女性，61 名男性），37%的患者疣存在时间超过 5 年。大多数（93%）患者已经尝试过冷冻疗法，但在所有情况下都未能完全清除疣。在接受 DCP 治疗后，77%的患者实现了疣的完全清除，包括 3 名免疫抑制患者。实现完全清除所需的 DCP 治疗次数平均为 4.7 次，所需的 DCP 浓度平均为 4%。只有 12%的患者出现了轻度不良反应，包括荨麻疹和水疱。
我们认为 DCP 免疫疗法是一种安全有效的治疗方法，可根除病毒性疣，特别是在难治性病例中。
